Review your caloric intake, as the medication reduces appetite but does not prevent weight gain if calorie consumption remains excessive
We have to look at patients holistically, who have kidney disease and diabetes, to address the totality of risks, certainly progression to kidney failure, but also prevention of cardiovascular events and deaths. Ozempic and other GLP-1s will be compared to another diabetes drug class, SGLT-2 inhibitors Given Ozempics reduction of kidney disease events in the FLOW study, it seems likely that the GLP-1s will be used together with and compared against SGLT-2 inhibitor drugs
Ongoing Support Get unlimited online access to follow-ups, adjustments, and answers to questions
For example, kidney function, liver health, and metabolism can slightly shorten or extend the 5-week window